SpotDoc Logo
Contact
All articlesResearch

The Melanoma mRNA Vaccine Passes a Phase 3 Test: What It Means

A personalized mRNA treatment for high-risk melanoma lowered the chance of cancer coming back in a large Phase 3 trial. Here's what the research shows, and the important limits to keep in mind.

Tyler Long, DOOctober 13, 20266 min read
The Melanoma mRNA Vaccine Passes a Phase 3 Test: What It Means

Updated November 18, 2026: added the published Phase 3 results.

A closely watched story in cancer research over the past few years has been a personalized mRNA vaccine for melanoma. In November 2026, it reached a new checkpoint: a large Phase 3 trial was published, and it showed fewer people had their cancer come back. It's an encouraging result worth understanding, along with the limits that the headlines often skip.

What This Vaccine Actually Is

The therapy is developed by Moderna and Merck. It was known in trials as mRNA-4157 / V940 and is now named intismeran autogene. It is not a vaccine in the way we usually mean the word. It does not prevent melanoma. It is a treatment for people who already have high-risk melanoma, designed to lower the chance that it comes back after surgery.

It is also personalized to each patient. After a melanoma is removed, the tumor is genetically sequenced to identify mutations unique to that person's cancer. A custom mRNA therapy is then manufactured to teach the immune system to recognize up to several dozen of those tumor-specific markers. It is given together with the established immunotherapy drug pembrolizumab (Keytruda), not on its own.

The same mRNA technology platform behind the COVID-19 vaccines is being applied here, but to a very different problem: training the immune system against an individual's cancer.

What the Research Shows

In the Phase 2b trial known as KEYNOTE-942, published in The Lancet in 20241, patients with resected high-risk (stage IIIB to IV) melanoma received either pembrolizumab alone or pembrolizumab plus the personalized vaccine.

  • Fewer people who got the vaccine had their cancer come back or died: 22% (24 of 107) versus 40% (20 of 50) with pembrolizumab alone. This was a small, open-label trial, and the result fell just short of the usual bar for statistical significance (p=0.053).1
  • A five-year update, published in the Journal of Clinical Oncology in 2026, reported a hazard ratio of 0.51 for cancer coming back or death. The authors called these five-year results descriptive, which means they were not a formal test.2

The larger Phase 3 trial has now reported. See the next section. The same approach is also being tested in other cancers, including lung cancer.3

The Phase 3 Results

In November 2026, the larger Phase 3 trial, called INTerpath-001, was published in the New England Journal of Medicine.4 It included 1,137 people whose Stage IIB, IIC, III, or IV melanoma had been fully removed by surgery. Everyone got pembrolizumab. Two out of three people also got intismeran. The rest got a placebo, a look-alike shot with no medicine in it. Neither the patients nor their doctors knew who got which.

  • Cancer coming back. At 2 years, 82.2% of people in the intismeran group had not had their cancer come back. In the placebo group, it was 70.0%.4
  • Spread to distant organs. At 2 years, 88.5% in the intismeran group had no spread to distant organs, compared with 80.2% in the placebo group.4
  • Timing. In the first 6 months, the two groups did about the same. The difference showed up after that.4
  • Health problems during the study. Health problems rated grade 3 or higher, whether or not caused by the treatment, happened in 23.6% of the intismeran group and 20.3% of the placebo group. Eight people in the intismeran group died from a health problem during the study (an adverse event). Five of those eight deaths happened before they had received any intismeran.4
  • What we don't know yet. The published results do not include overall survival, so we do not know yet if the treatment helps people live longer. People in the study were followed for a median of about 2 years.4

The treatment is not FDA-approved. The companies say they are working toward submitting it to regulators. For now, it is available only in clinical trials, and the melanoma studies of this treatment are not taking new patients. If you or a family member has high-risk melanoma that was removed by surgery, ask your cancer specialist whether this treatment may become an option for you.

The Important Caveats

This is genuinely promising science, and it deserves an honest frame:

  • It is still investigational. As of November 2026 it is not FDA-approved. The companies say they are working toward submitting it to regulators. Until then, it is available only in clinical trials, and the melanoma studies of this treatment are not taking new patients.
  • It is a treatment, not a prevention. It is for people who have already been diagnosed with high-risk melanoma and had it surgically removed. It is not a shot to prevent melanoma in the general population.
  • It is given through oncology, in combination with immunotherapy. Right now it is given only within clinical trials at cancer centers, not as a dermatology office service.
  • The Phase 3 results are early. People were followed for about two years. We do not yet know if the treatment helps people live longer. The benefit did not show up in the first six months.

Why It Still Comes Back to Early Detection

Here's the part that connects this frontier science to everyday skin care: this therapy exists to help people whose melanoma was caught at a high-risk, already-invasive stage. Finding melanoma early is still the key step against it. Early melanoma can often be cured by surgery alone, before any of this is needed.

Early-stage melanoma caught before it spreads has a five-year survival rate above 99%.5 That number is the reason regular skin checks and prompt evaluation of changing spots still matter more than any single new treatment. Advances like the mRNA vaccine are a hopeful safety net for high-risk disease. They are not a substitute for catching melanoma early.

If you want a refresher on what to watch for, see our guide to melanoma, and our guide to checking your own skin.

The Bottom Line

A personalized mRNA treatment added to immunotherapy lowered the chance of melanoma coming back in a large Phase 3 trial. An earlier, smaller trial saw a similar pattern over five years. It is a hopeful result for high-risk patients, but it is not yet FDA-approved, and we do not know yet if it helps people live longer. It does not prevent melanoma and isn't yet standard care, but it points toward a future where the immune system can be taught to guard against a specific person's cancer. In the meantime, early detection remains the foundation.

References

  1. Weber JS, Carlino MS, Khattak A, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. The Lancet. 2024;403(10427):632–644. thelancet.com ↩ ↩2

  2. Khattak A, Carlino MS, Meniawy T, et al. Intismeran autogene plus pembrolizumab versus pembrolizumab alone in high-risk resected melanoma: 5-year update of the randomized phase IIb KEYNOTE-942 study. J Clin Oncol. 2026;44(26):2482-2489. doi.org ↩

  3. Spicer JD, Peters S, Gainor JF, et al. Study designs for INTerpath-002 and INTerpath-009 of adjuvant intismeran autogene plus pembrolizumab for non-small cell lung cancer. Ann Thorac Surg Short Rep. 2026;4(3):903-908. doi.org ↩

  4. Long GV, Khattak MA, Gogas HJ, et al. Intismeran autogene plus pembrolizumab for resected stage IIB to IV melanoma. N Engl J Med. Published online November 11, 2026. doi.org ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  5. American Cancer Society. Survival Rates for Melanoma Skin Cancer. cancer.org ↩

melanomamRNA vaccineimmunotherapyresearchclinical trials

Worried about a spot? We can take a look.

SpotDoc offers full-body skin cancer screening in The Villages. No referral needed for most plans.